Coronavirus Update: Roche's Actemra Fails In Phase III COVID Study
Plus: Favipiravir Market Heating Up In India
Disappointment as Roche/Chugai antibody tocilizumab misses most endpoints.
You may also be interested in...
South Korea approves AstraZeneca’s COVID-19 Vaccine, while Actemra moves forward in Japan after local study results.
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.
A study presented at a recent MIT-sponsored conference used network medicine to uncover dozens of potential opportunities for existing drugs to be repurposed for COVID-19.